(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies - 2Find Your Internal Culinary expert: Cooking Strategies and Recipes
- 3Kendall Jenner addresses long-standing rumor about her sexuality
- 4Japan deploys the military to counter a surge in bear attacks
- 5This St Nick Truly Can Advise How To Drink And Hack Your Headache
- Where America’s CO2 emissions come from – what you need to know, in charts
- The Way to Business: Startup Illustrations Learned
- Why this Tennessee special election has the 'whole world' watching
- Vote In favor of Your Favored Kind Of Tea
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- ‘It’s Israeli policy’: Report reveals abuse of Palestinians in prisons
- Public Parks in the USA
